A preclinical study confirmed the low levels of BRCA1 expression in AML primary samples and cell lines and suggested that this low expression may underlie the sensitivity of these samples to the PARP inhibitor olaparib [119]. The gene discussed is BRCA1; the disease is acute myeloid leukemia.